Details of the Drug

General Information of Drug (ID: DMRBMAU)

• Drug Name: Mycophenolic acid
• Synonyms: Micofenolico acido; Micofenolico acido [Spanish]; Mycophenoic acid; Mycophenolate; Mycophenolsaeure; Myfortic; mycophenolic acid; Acide mycophenolique; Acido micofenolico; Acido micofenolico [INN-Spanish]; Acidum mycophenolicum; Lilly-68618; Ly 68618; Melbex; (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; 24280-93-1; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; CCRIS 5565; NSC 129185; NSC-129185; UNII-HU9DX48N0T

Indication

Disease Entry	ICD 11	Status	REF
Crohn disease	DD70	Approved	[1]
Hepatosplenic T-cell lymphoma	N.A.	Approved	[2]
Interstitial cystitis	GC00.3	Approved	[3]
Large granular lymphocytic leukemia	2A90.1	Approved	[2]
Leukemia	N.A.	Approved	[4]
Lupus nephritis	4A40.0Y	Approved	[5]
MALT lymphoma	N.A.	Approved	[2]
Myeloid leukaemia	2B33.1	Approved	[6]
Myeloproliferative neoplasm	2A20	Approved	[7]
Nodal marginal zone lymphoma	2A85.0	Approved	[2]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified	N.A.	Approved	[2]
Recurrent adult burkitt lymphoma	2A85.6	Approved	[2]
Small intestine lymphoma	N.A.	Approved	[2]
Splenic marginal zone lymphoma	N.A.	Approved	[2]
Systemic lupus erythematosus	4A40.0	Approved	[8]
Testicular lymphoma	N.A.	Approved	[2]
Classic Hodgkin lymphoma	N.A.	Investigative	[9]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[10]
Middle East Respiratory Syndrome (MERS)	1D64	Investigative	[11]

• Affected Organisms: Humans and other mammals
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 320.3
  Logarithm of the Partition Coefficient (xlogp); 3.2
  Rotatable Bond Count (rotbonds); 6
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 6
• Chemical Identifiers:
  Formula: C17H20O6
  IUPAC Name: (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
  Canonical SMILES: CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O
  InChI: InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
  InChIKey: HPNSFSBZBAHARI-RUDMXATFSA-N
• Cross-matching ID:
  PubChem CID: 446541
  ChEBI ID: CHEMBL866
  CAS Number: 483-60-3
  UNII: HU9DX48N0T
  DrugBank ID: DB01024
  INTEDE ID: DR1119
• Drug-Molecule Activity Atlas (DMA)NEW: Click to Jump to the Detailed DMA Information of This Drug
• Drug Pharmacogenomic Perturbation (DPP)NEW: Click to Jump to the Detailed DPP Information of This Drug
• Drug ADMET Endpoint Profile (DAE)NEW: Click to Jump to the Detailed DAE Information of This Drug
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
MERS-CoV papain-like proteinase (PL-PRO)	TTYJOLE	R1AB_CVEMC (854-2740)	Inhibitor	[11]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[12]
Organic anion transporter 1 (SLC22A6)	DTQ23VB	S22A6_HUMAN	Substrate	[13]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Substrate	[14]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[14]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mycophenolic acid (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Moderate	Decreased absorption of Mycophenolic acid due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[15]
Clindamycin	DM15HL8	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Clindamycin.	Acne vulgaris [ED80]	[16]
Cefuroxime	DMSIMD8	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefuroxime.	Acute bronchitis [CA42]	[16]
Paromomycin	DM1AGXN	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Paromomycin.	Amoebiasis [1A36]	[16]
Cefamandole	DMNEXZF	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefamandole.	Anaerobic bacterial infection [1A00-1A09]	[16]
Aminophylline	DML2NIB	Minor	Increased plasma concentration of Mycophenolic acid and Aminophylline due to competitive binding of plasma proteins.	Asthma [CA23]	[16]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Mycophenolic acid and Roflumilast.	Asthma [CA23]	[17]
Cefotetan	DM07TX3	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefotetan.	Bacterial infection [1A00-1C4Z]	[16]
Ofloxacin	DM0VQN3	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Oritavancin	DM28D05	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Oritavancin.	Bacterial infection [1A00-1C4Z]	[16]
Kanamycin	DM2DMPO	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Kanamycin.	Bacterial infection [1A00-1C4Z]	[16]
Ceftizoxime	DM3VOGS	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Ceftizoxime.	Bacterial infection [1A00-1C4Z]	[16]
Dalfopristin	DM4LTKV	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Dalfopristin.	Bacterial infection [1A00-1C4Z]	[16]
Clarithromycin	DM4M1SG	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Clarithromycin.	Bacterial infection [1A00-1C4Z]	[16]
Ticarcillin	DM4ME02	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Ticarcillin.	Bacterial infection [1A00-1C4Z]	[16]
Cefoperazone	DM53PV8	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefoperazone.	Bacterial infection [1A00-1C4Z]	[16]
Cefprozil	DM7DSYP	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefprozil.	Bacterial infection [1A00-1C4Z]	[16]
Sparfloxacin	DMB4HCT	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Ceftriaxone	DMCEW64	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Ceftriaxone.	Bacterial infection [1A00-1C4Z]	[16]
Streptomycin	DME1LQN	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Streptomycin.	Bacterial infection [1A00-1C4Z]	[16]
Dalbavancin	DMGMNH3	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Dalbavancin.	Bacterial infection [1A00-1C4Z]	[16]
Gemifloxacin	DMHT34O	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Cefepime	DMHVWIK	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefepime.	Bacterial infection [1A00-1C4Z]	[16]
Imipenem	DMI9FBP	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Imipenem.	Bacterial infection [1A00-1C4Z]	[16]
Meticillin	DMIKHN0	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Meticillin.	Bacterial infection [1A00-1C4Z]	[16]
Norfloxacin	DMIZ6W2	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[16]
ABT-492	DMJFD2I	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[16]
Cefpodoxime	DMJUNY5	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefpodoxime.	Bacterial infection [1A00-1C4Z]	[16]
Cefadroxil	DMMC345	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefadroxil.	Bacterial infection [1A00-1C4Z]	[16]
Bacampicillin	DMP54C7	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Bacampicillin.	Bacterial infection [1A00-1C4Z]	[16]
Cefazolin	DMPDYFR	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefazolin.	Bacterial infection [1A00-1C4Z]	[16]
Novobiocin	DMRFWGK	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Novobiocin.	Bacterial infection [1A00-1C4Z]	[16]
Levofloxacin	DMS60RB	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Cefditoren	DMSUVM1	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefditoren.	Bacterial infection [1A00-1C4Z]	[16]
Cefonicid	DMTX2BH	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefonicid.	Bacterial infection [1A00-1C4Z]	[16]
Cefradine	DMUNSWV	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefradine.	Bacterial infection [1A00-1C4Z]	[16]
Cloxacillin	DMUTL7O	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cloxacillin.	Bacterial infection [1A00-1C4Z]	[16]
Amoxicillin	DMUYNEI	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Amoxicillin.	Bacterial infection [1A00-1C4Z]	[16]
Troleandomycin	DMUZNIG	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Troleandomycin.	Bacterial infection [1A00-1C4Z]	[16]
Cefoxitin	DMY8NC4	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefoxitin.	Bacterial infection [1A00-1C4Z]	[16]
Ceftibuten	DMWV2AG	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Ceftibuten.	Bronchitis [CA20]	[16]
Oxtriphylline	DMLHSE3	Minor	Increased plasma concentration of Mycophenolic acid and Oxtriphylline due to competitive binding of plasma proteins.	Cough [MD12]	[16]
SODIUM CITRATE	DMHPD2Y	Moderate	Decreased absorption of Mycophenolic acid due to altered gastric pH caused by SODIUM CITRATE.	Discovery agent [N.A.]	[15]
Benzylpenicillin	DMS9503	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Benzylpenicillin.	Discovery agent [N.A.]	[16]
Fosphenytoin	DMOX3LB	Minor	Increased plasma concentration of Mycophenolic acid and Fosphenytoin due to competitive binding of plasma proteins.	Epilepsy/seizure [8A61-8A6Z]	[16]
Lincomycin	DMVTHER	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Lincomycin.	Gram-positive bacterial infection [1B74-1F40]	[16]
Rifampin	DMA8J1G	Major	Increased metabolism of Mycophenolic acid caused by Rifampin mediated induction of UGT.	HIV-infected patients with tuberculosis [1B10-1B14]	[17]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Mycophenolic acid and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[18]
TP-434	DM5A31S	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by TP-434.	Infectious gastroenteritis/colitis [1A40]	[16]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Mycophenolic acid and Denosumab.	Low bone mass disorder [FB83]	[19]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Mycophenolic acid caused by PF-06463922 mediated induction of UGT.	Lung cancer [2C25]	[20]
Sulphadoxine	DMZI2UF	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Sulphadoxine.	Malaria [1F40-1F45]	[16]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Mycophenolic acid due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[21]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Mycophenolic acid and Tecfidera.	Multiple sclerosis [8A40]	[22]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Mycophenolic acid and Siponimod.	Multiple sclerosis [8A40]	[20]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Mycophenolic acid and Fingolimod.	Multiple sclerosis [8A40]	[23]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Mycophenolic acid and Ocrelizumab.	Multiple sclerosis [8A40]	[24]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Mycophenolic acid and Ozanimod.	Multiple sclerosis [8A40]	[17]
Gatifloxacin	DMSL679	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[16]
Colistimethate	DMZ9BMU	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Colistimethate.	Respiratory infection [CA07-CA4Z]	[16]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Mycophenolic acid and Canakinumab.	Rheumatoid arthritis [FA20]	[25]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Mycophenolic acid and Rilonacept.	Rheumatoid arthritis [FA20]	[25]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Mycophenolic acid and Golimumab.	Rheumatoid arthritis [FA20]	[26]
Leflunomide	DMR8ONJ	Major	Additive myelosuppressive effects by the combination of Mycophenolic acid and Leflunomide.	Rheumatoid arthritis [FA20]	[18]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Mycophenolic acid when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[27]
Cephapirin	DMV2JNY	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cephapirin.	Sepsis [1G40-1G41]	[16]
Tedizolid	DMG2SKR	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Tedizolid.	Skin and skin-structure infection [1F28-1G0Z]	[16]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Mycophenolic acid caused by Pitolisant mediated induction of UGT.	Somnolence [MG42]	[17]
Doripenem	DM9UCJK	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Doripenem.	Urinary tract infection [GC08]	[16]
Plazomicin	DMKMBES	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Plazomicin.	Urinary tract infection [GC08]	[16]
Secnidazole	DMJ18YL	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Secnidazole.	Vaginal discharge [MF3A]	[16]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [3] Early termination of a trial of mycophenolate mofetil for treatment of interstitial cystitis/painful bladder syndrome: lessons learned. J Urol. 2011 Mar;185(3):901-6.
• [4] New conjugates of mycophenolic acid and their antiproliferative activity. J Asian Nat Prod Res. 2016 Nov;18(11):1057-62.
• [5] 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723.
• [6] Mycophenolic Acid overcomes imatinib and nilotinib resistance of chronic myeloid leukemia cells by apoptosis or a senescent-like cell cycle arrest. Leuk Res Treatment. 2012;2012:861301.
• [7] Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 Jul;25(7):1407-1415.
• [8] Systemic Lupus Erythematosus Management in Pregnancy. Int J Womens Health. 2022 Feb 15;14:199-211.
• [9] Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database. Pathol Res Pract. 2018 Nov;214(11):1854-1867.
• [10] Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020 Mar 27;14:1022.
• [11] SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016 Aug;14(8):523-34.
• [12] C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics. 2007 Sep;8(9):1127-41.
• [13] Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. Biochem Pharmacol. 2007 Jun 30;74(1):161-8.
• [14] Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55.
• [15] Bullingham R, Shah J, Goldblum R, Schiff M "Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients." Br J Clin Pharmacol 41 (1996): 513-6. [PMID: 8799515]
• [16] Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
• [17] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [18] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [19] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [20] Cerner Multum, Inc. "Australian Product Information.".
• [21] Canadian Pharmacists Association.
• [22] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [23] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [24] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [25] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [26] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [27] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]